Overview

Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as vorinostat and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat and capecitabine in treating patients with unresectable or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
University Health Network, Toronto
Collaborator:
National Cancer Institute (NCI)
Treatments:
Capecitabine
Vorinostat